<DOC>
	<DOCNO>NCT00004262</DOCNO>
	<brief_summary>Phase I trial study effectiveness radiation therapy gadolinium texaphyrin treat patient supratentorial glioblastoma multiforme . Radiation therapy use high-energy x-rays damage tumor cell . Drugs gadolinium texaphyrin may make tumor cell sensitive radiation therapy .</brief_summary>
	<brief_title>Radiation Therapy Gadolinium Texaphyrin Treating Patients With Supratentorial Glioblastoma Multiforme</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine frequency grade toxicity gadolinium texaphyrin radiosensitizer two dose level patient supratentorial glioblastoma multiforme undergo stereotactic radiosurgery . II . Compare tumor , normal brain , plasma concentration drug regimen 1.5 8 Tesla MRI image patient population . III . Determine 8 Tesla image provide data 1.5 Tesla image term radiosensitizing drug distribution tumor patient . OUTLINE : This dose escalation study . Within 5 week follow surgery , patient receive daily external beam radiotherapy five day week 5 week . Within 2 week follow completion radiotherapy , patient receive gadolinium texaphyrin IV 2 hour follow 3 hour later stereotactic radiosurgery . Patients undergo surgical debulking tumor prior external beam radiotherapy receive gadolinium texaphyrin IV 2 hour , 3 hour prior surgery addition dose prior stereotactic radiosurgery . Cohorts 3-6 patient receive escalate dos gadolinium texaphyrin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow monthly 3 month , every 3 month 5 year death . PROJECTED ACCRUAL : Approximately 12-18 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>Histologically confirm supratentorial glioblastoma multiforme stereotactic biopsy , open biopsy , resection Maximum diameter tumor mass must great 4 cm dimension , include follow debulking surgery Tumor must least 1.0 cm optic chiasm brainstem No oligodendrogliomas , meningioma , grade I , II , III astrocytomas No infratentorial tumor No multifocal glioblastoma multiforme Tumor enhance MRI Must visible tumor postoperative MRI follow surgical resection Performance status Karnofsky 60100 % At least 3 month Hemoglobin least 10.0 g/dL Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL SGPT great 60 U/L Creatinine great 1.3 mg/dL Blood urea nitrogen great 24 mg/dL Neurological function status 03 No evidence neuropathy No glucose6phosphate dehydrogenase deficiency No known history porphyria History prior malignancy allow HIV positive status allow No medical contraindication MRI imaging ( i.e. , pacemaker , aneurysm clip , nonsecure metal fragment close critical structure ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior study At least 6 week since prior chemotherapy Concurrent steroid allow No prior radiotherapy brain upper neck No great 5 week since prior surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>